Literature DB >> 29669246

TGF-β Inhibition and Immunotherapy: Checkmate.

Karuna Ganesh1, Joan Massagué2.   

Abstract

Immune checkpoint therapy can induce durable remissions, but many tumors demonstrate resistance. In a recent issue of Nature, Mariathasan et al. (2018) and Tauriello et al. (2018) identify stromal TGF-β signaling as a determinant of immune exclusion. Combination TGF-β inhibition and immunotherapy induces complete responses in mouse models.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29669246      PMCID： PMC6347120          DOI： 10.1016/j.immuni.2018.03.037

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  10 in total

Review 1.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

Review 2.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

3.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.

Authors:  Daniele V F Tauriello; Sergio Palomo-Ponce; Diana Stork; Antonio Berenguer-Llergo; Jordi Badia-Ramentol; Mar Iglesias; Marta Sevillano; Sales Ibiza; Adrià Cañellas; Xavier Hernando-Momblona; Daniel Byrom; Joan A Matarin; Alexandre Calon; Elisa I Rivas; Angel R Nebreda; Antoni Riera; Camille Stephan-Otto Attolini; Eduard Batlle
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

Review 4.  Targeting the TGFβ pathway for cancer therapy.

Authors:  Cindy Neuzillet; Annemilaï Tijeras-Raballand; Romain Cohen; Jérôme Cros; Sandrine Faivre; Eric Raymond; Armand de Gramont
Journal:  Pharmacol Ther       Date:  2014-11-06       Impact factor: 12.310

Review 5.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

6.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.

Authors:  Alexandre Calon; Enza Lonardo; Antonio Berenguer-Llergo; Elisa Espinet; Xavier Hernando-Momblona; Mar Iglesias; Marta Sevillano; Sergio Palomo-Ponce; Daniele V F Tauriello; Daniel Byrom; Carme Cortina; Clara Morral; Carles Barceló; Sebastien Tosi; Antoni Riera; Camille Stephan-Otto Attolini; David Rossell; Elena Sancho; Eduard Batlle
Journal:  Nat Genet       Date:  2015-02-23       Impact factor: 38.330

Review 7.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 8.  The roles of TGFβ in the tumour microenvironment.

Authors:  Michael Pickup; Sergey Novitskiy; Harold L Moses
Journal:  Nat Rev Cancer       Date:  2013-10-17       Impact factor: 60.716

Review 9.  Combination immunotherapy: a road map.

Authors:  Patrick A Ott; F Stephen Hodi; Howard L Kaufman; Jon M Wigginton; Jedd D Wolchok
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962
  10 in total
  35 in total

1.  Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.

Authors:  Upender Velaparthi; Chetan Padmakar Darne; Jayakumar Warrier; Peiying Liu; Hasibur Rahaman; Karen Augustine-Rauch; Karen Parrish; Zheng Yang; Jesse Swanson; Jennifer Brown; Gopal Dhar; Aravind Anandam; Vinay K Holenarsipur; Kamalavenkatesh Palanisamy; Barri S Wautlet; Mark P Fereshteh; Jonathan Lippy; Andrew J Tebben; Steven Sheriff; Max Ruzanov; Chunhong Yan; Anuradha Gupta; Arun Kumar Gupta; Muthalagu Vetrichelvan; Arvind Mathur; Marina Gelman; Rajinder Singh; Todd Kinsella; Anwar Murtaza; Joseph Fargnoli; Gregory Vite; Robert M Borzilleri
Journal:  ACS Med Chem Lett       Date:  2020-01-28       Impact factor: 4.345

Review 2.  Coming of Age of Immunotherapy of Urothelial Cancer.

Authors:  Enrique Grande; Javier Molina-Cerrillo; Andrea Necchi
Journal:  Target Oncol       Date:  2021-03-12       Impact factor: 4.493

Review 3.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 4.  Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.

Authors:  Dana L Casey; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2020-02       Impact factor: 11.151

5.  Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells.

Authors:  Yuxuan Miao; Hanseul Yang; John Levorse; Shaopeng Yuan; Lisa Polak; Megan Sribour; Bhuvanesh Singh; Michael D Rosenblum; Elaine Fuchs
Journal:  Cell       Date:  2019-04-25       Impact factor: 41.582

6.  CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.

Authors:  Viktória Golumba-Nagy; Johannes Kuehle; Andreas A Hombach; Hinrich Abken
Journal:  Mol Ther       Date:  2018-07-10       Impact factor: 11.454

Review 7.  Cancer Stem Cells: The Architects of the Tumor Ecosystem.

Authors:  Briana C Prager; Qi Xie; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2019-01-03       Impact factor: 24.633

8.  Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.

Authors:  Erika J Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R Nair; Yingmiao Liu; Elizabeth M Swisher; James W Hodge; Andrew B Nixon; Erin Nichols; Mohammad H Bagheri; Elliott Levy; Marc R Radke; Stanley Lipkowitz; Christina M Annunziata; Janis M Taube; Seth M Steinberg; Jung-Min Lee
Journal:  Clin Cancer Res       Date:  2020-05-12       Impact factor: 12.531

9.  Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy.

Authors:  Nils Ludwig; Łukasz Wieteska; Cynthia S Hinck; Saigopalakrishna S Yerneni; Juliana H Azambuja; Richard J Bauer; Torsten E Reichert; Andrew P Hinck; Theresa L Whiteside
Journal:  Mol Cancer Ther       Date:  2021-04-13       Impact factor: 6.261

10.  Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors.

Authors:  Peter A Bielecki; Morgan E Lorkowski; Wyatt M Becicka; Prabhani U Atukorale; Taylor J Moon; Yahan Zhang; Michelle Wiese; Gil Covarrubias; Shruthi Ravichandran; Efstathios Karathanasis
Journal:  Nanoscale Horiz       Date:  2021-01-05       Impact factor: 10.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.